Literature DB >> 25837828

Towards interferon-free treatment for all HCV genotypes.

Heiner Wedemeyer1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25837828     DOI： 10.1016/S0140-6736(15)60605-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

Review 1.  [Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects].

Authors:  K Deterding; M P Manns; H Wedemeyer
Journal:  Internist (Berl)       Date:  2018-04       Impact factor: 0.743

Review 2.  Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review.

Authors:  Trana Hussaini
Journal:  Hepat Med       Date:  2016-05-18

3.  The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.

Authors:  Jim Young; Nina Weis; Harald Hofer; William Irving; Ola Weiland; Emiliano Giostra; Juan Manuel Pascasio; Lluis Castells; Martin Prieto; Roelien Postema; Cinira Lefevre; David Evans; Heiner C Bucher; Jose Luis Calleja
Journal:  BMC Infect Dis       Date:  2017-01-07       Impact factor: 3.090

4.  The association between implementation strategy use and the uptake of hepatitis C treatment in a national sample.

Authors:  Shari S Rogal; Vera Yakovchenko; Thomas J Waltz; Byron J Powell; JoAnn E Kirchner; Enola K Proctor; Rachel Gonzalez; Angela Park; David Ross; Timothy R Morgan; Maggie Chartier; Matthew J Chinman
Journal:  Implement Sci       Date:  2017-05-11       Impact factor: 7.327

5.  SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China.

Authors:  Yanhua Li; Jiuping Wang; Juan Wang; Yunfeng Xiao; Bin Xu; Hongwei Li; Liu Yang; Xiaoke Hao; Yueyun Ma
Journal:  Virol J       Date:  2017-03-23       Impact factor: 4.099

6.  Hepatitis Screening and Treatment Campaign in Malaysia-Validation of Low-cost Point of Care Screening Tests and Nucleic Acid Tests for Hepatitis B and C.

Authors:  Muhammad Radzi Ah; Soek S Tan; Rosmawati Mohamed; Fauziah Jaya; Senamjit K; Azlida C Aun; Ghazali A Kutty; Hin S Wong; Rafidah Abdullah; Mohd R Seman; Mamun Al Mahtab; Zaki Morad; Teck-Onn Lim
Journal:  Euroasian J Hepatogastroenterol       Date:  2019-02-01

7.  Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2.

Authors:  Shari S Rogal; Vera Yakovchenko; Thomas J Waltz; Byron J Powell; Rachel Gonzalez; Angela Park; Maggie Chartier; David Ross; Timothy R Morgan; JoAnn E Kirchner; Enola K Proctor; Matthew J Chinman
Journal:  Implement Sci       Date:  2019-04-08       Impact factor: 7.327

8.  Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.

Authors:  Chi-Chieh Yang; Wei-Lun Tsai; Wei-Wen Su; Chung-Feng Huang; Pin-Nan Cheng; Ching-Chu Lo; Kuo-Chih Tseng; Lein-Ray Mo; Chun-Hsiang Wang; Shih-Jer Hsu; Hsueh-Chou Lai; Chien-Wei Su; Chun-Jen Liu; Cheng-Yuan Peng; Ming-Lung Yu
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

9.  Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy.

Authors:  Sarina Ravens; Julia Hengst; Verena Schlapphoff; Katja Deterding; Akshay Dhingra; Christian Schultze-Florey; Christian Koenecke; Markus Cornberg; Heiner Wedemeyer; Immo Prinz
Journal:  Front Immunol       Date:  2018-03-16       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.